CSIMarket


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 


 

Integrated Biopharma Inc

INBP's Financial Statements and Analysis



Integrated Biopharma Inc reported in the second quarter of 2024 net loss per share of $-0.01 compare to earnings per share of $0.03 in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


second quarter of 2024
Earnings Per Share Revenues
$ -0.01 $  11 Mill
$-0.04     $-2M     -14.15 %



Integrated Biopharma Inc's Revenue fell by -14.15 % in second quarter of 2024 (Dec 31 2023) year on year, to $11 million and declined by -18.02 % sequentially.


Integrated Biopharma Inc is

More on INBP's Income Statement



Integrated Biopharma Inc's in thesecond quarter of 2024 recorded net loss of $-0.382 million, an increase from net loss of $-0.055 million in II. Quarter a year ago.

Sequentially net loss advanced

More on INBP's Growth

Integrated Biopharma Inc Inventories
Inventories grew by 18.37 % to $12 million from II. Quarter a year ago, sequentially inventories rose by 15.58 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-2 million, capital expenditures grew by -0.032-25.00%, to $0 millions compare to same quarter a year ago

More on INBP's Cash flow Statement


Integrated Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Integrated Biopharma Inc payed $ -0.01 cash per share, on a free-cash flow basis .

Book value fell by -2.13 % sequentially to $0.62 per share, -144.36% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.62 per share from $ 0.63.

Company issued 0.13 million shares or 0.45 % in Dec 31 2023.


More on INBP's Dividends

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 30
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Integrated Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Integrated Biopharma Inc had negative $ -0.01 cash flow per share, on a free-cash flow basis .

Book value fell by -2.13 % sequentially to $0.62 per share, -144.36% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.62 per share from $ 0.63.

Company issued 0.13 million shares or 0.45 % in Dec 31 2023.


More on INBP's Balance Sheets

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 30
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Integrated Biopharma Inc Earnings

Integrated Biopharma Inc Faces Alarming Decline in Q2 2024 Revenue

Integrated Biopharma Inc is a pharmaceutical company that operates in the Major Pharmaceutical Preparations industry. In the most recent fiscal period, the company experienced a loss of $0.01 per share, compared to a profit of $0.03 per share the previous year and break-even results in the preceding financial reporting period. This decline in profitability is concerning for investors as it indicates a downward trend in the company's financial performance.
One of the main reasons for the decline in profitability is the substantial decrease in revenue. Compared to the same period last year, revenue decreased by 14.15% to $10.52 million, and sequentially, revenue fell by 18.017% from $12.83 million. This dr...

Integrated Biopharma Inc Achieves Promising 4.105% Growth in Q3 FY 2023

During the past week, Integrated Biopharma Inc (IBI) experienced a slight increase in its shares by 1.12%. This brings the year-to-date performance for IBI to a significant decrease of -23.27%. Currently, IBI shares are trading at a significant discount of -22.5% below its 52-week average.
In terms of financial performance, IBI reported its most recent fiscal period with zero earnings per share (EPS), compared to the same period the previous year. This is also consistent with the preceding quarter. However, despite the lack of earnings, IBI's revenue saw a slight increase of 4.105% to $12.83 million, compared to $12.33 million in the same quarter a year ago. Sequentially, the company's revenue increased ...

INBPsn Unveil Latest Financial Results



Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with th...

Integrated Biopharma Inc's Revenue Plummeted by -16.221% in Q3 2023: A Detailed Analysis

Integrated Biopharma Inc's Fiscal Third Quarter of 2023: Insights and Analysis
Integrated Biopharma Inc, a healthcare company operating in the United States, has recently released its financial results for the fiscal third quarter of 2023. In this article, we will delve into the details of the report and provide insights and analysis into the company's performance.
The report shows that Integrated Biopharma Inc reached zero gain of $0.00 per share for the fiscal third quarter of 2023, in comparison to $0.03 per share in the same quarter a year earlier and in the preceding quarter. Correspondingly, revenue declined by -16.221% to $13.10 million from $15.63 million in the same quarter a year earlier, b...


Date modified: 2024-02-13T09:07:52+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com